Akcea Therapeutics Inc logo

AKCA - Akcea Therapeutics Inc Share Price

$15.24 0.4  3.0%

Last Trade - 05/06/20

Mid Cap
Market Cap £1.22bn
Enterprise Value £889.0m
Revenue £269.1m
Position in Universe 1998th / 6325
Unlock AKCA Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Akcea Therapeutics Inc revenues decreased 90% to $16.1M. Net loss totaled $42.9M vs. income of $27.2M. Revenues reflect Research and development and license revenue under segment decrease of 99% to $915K. Net loss reflects Selling/General/Admin. E increase of 35% to $40.6M (expense), Net loss share from commercial activitie decrease of 22% to $7.1M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AKCA Revenue Unlock AKCA Revenue

Net Income

AKCA Net Income Unlock AKCA Revenue

Normalised EPS

AKCA Normalised EPS Unlock AKCA Revenue

PE Ratio Range

AKCA PE Ratio Range Unlock AKCA Revenue

Dividend Yield Range

AKCA Dividend Yield Range Unlock AKCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AKCA EPS Forecasts Unlock AKCA Revenue
Profile Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated December 22, 2014
Public Since July 14, 2017
No. of Shareholders: 11
No. of Employees: 294
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 101,509,223
Free Float (0.0%)
Eligible for
AKCA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AKCA
Upcoming Events for AKCA
Friday 12th June, 2020 Estimate
Akcea Therapeutics Inc Annual Shareholders Meeting
Tuesday 4th August, 2020 Estimate
Q2 2020 Akcea Therapeutics Inc Earnings Release
Tuesday 3rd November, 2020 Estimate
Q3 2020 Akcea Therapeutics Inc Earnings Release
Frequently Asked Questions for Akcea Therapeutics Inc
What is the Akcea Therapeutics Inc share price?

As of 05/06/20, shares in Akcea Therapeutics Inc are trading at $15.24, giving the company a market capitalisation of £1.22bn. This share price information is delayed by 15 minutes.

How has the Akcea Therapeutics Inc share price performed this year?

Shares in Akcea Therapeutics Inc are currently trading at $15.24 and the price has moved by -29.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akcea Therapeutics Inc price has moved by -34.62% over the past year.

What are the analyst and broker recommendations for Akcea Therapeutics Inc?

Of the analysts with advisory recommendations for Akcea Therapeutics Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Akcea Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Akcea Therapeutics Inc next release its financial results?

Akcea Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Akcea Therapeutics Inc dividend yield?

Akcea Therapeutics Inc does not currently pay a dividend.

Does Akcea Therapeutics Inc pay a dividend?

Akcea Therapeutics Inc does not currently pay a dividend.

When does Akcea Therapeutics Inc next pay dividends?

Akcea Therapeutics Inc does not currently pay a dividend.

How do I buy Akcea Therapeutics Inc shares?

To buy shares in Akcea Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Akcea Therapeutics Inc?

Shares in Akcea Therapeutics Inc are currently trading at $15.24, giving the company a market capitalisation of £1.22bn.

Where are Akcea Therapeutics Inc shares listed? Where are Akcea Therapeutics Inc shares listed?

Here are the trading details for Akcea Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AKCA
What kind of share is Akcea Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Akcea Therapeutics Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Akcea Therapeutics Inc share price forecast 2020?

Shares in Akcea Therapeutics Inc are currently priced at $15.24. At that level they are trading at 90.29% discount to the analyst consensus target price of 0.00.

Analysts covering Akcea Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.624 for the next financial year.

How can I tell whether the Akcea Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akcea Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -12.95%. At the current price of $15.24, shares in Akcea Therapeutics Inc are trading at -12.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Akcea Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Akcea Therapeutics Inc.

Who are the key directors of Akcea Therapeutics Inc?

Akcea Therapeutics Inc's management team is headed by:

Christopher Gabrieli - IND
Louis O'Dea - OTH
Edward Fitzgerald - IND
Richard Moscicki - IND
Damien McDevitt - CEO
B. Lynne Parshall - CHM
Elaine Hochberg - IND
Joseph Klein - IND
Kyle Jenne - OTH
Alex Howarth - COO
Joshua Patterson - GCN
Carla Poulson - CHO
Michael Price - CFO
Who are the major shareholders of Akcea Therapeutics Inc?

Here are the top five shareholders of Akcea Therapeutics Inc based on the size of their shareholding:

Ionis Pharmaceuticals Inc Corporation
Percentage owned: 75.95% (77.1m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 10.54% (10.7m shares)
Novartis Pharma AG Corporation
Percentage owned: 6.16% (6.25m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.9% (4.97m shares)
Bellevue Asset Management AG Investment Advisor
Percentage owned: 3.16% (3.20m shares)
Similar to AKCA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.